Key Points
- Omada Health President Wei-Li Shao sold 5,618 shares on Dec. 29 at an average price of $16.13 for a total of $90,618.34, trimming his stake by 7.52% to 69,079 shares worth $1,114,244.27.
- OMDA opened at $15.34 and is trading near its 12‑month low of $14.14 (12‑month high $28.40), with a 50‑day moving average of $19.15 and a 200‑day moving average of $20.06.
- Analysts are broadly optimistic — the consensus rating is Moderate Buy with an average target of $27.11, and several firms have recently raised price targets while multiple institutional investors initiated positions.
Omada Health, Inc. (NASDAQ:OMDA - Get Free Report) President Wei-Li Shao sold 5,618 shares of Omada Health stock in a transaction on Monday, December 29th. The stock was sold at an average price of $16.13, for a total transaction of $90,618.34. Following the sale, the president owned 69,079 shares in the company, valued at $1,114,244.27. This represents a 7.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Omada Health Stock Performance
NASDAQ:OMDA opened at $15.34 on Wednesday. Omada Health, Inc. has a 12 month low of $14.14 and a 12 month high of $28.40. The company's 50-day moving average price is $19.15 and its two-hundred day moving average price is $20.06.
Wall Street Analysts Forecast Growth
OMDA has been the subject of several analyst reports. Needham & Company LLC boosted their target price on Omada Health from $26.00 to $28.00 and gave the stock a "buy" rating in a research report on Friday, November 7th. Barclays boosted their price target on Omada Health from $28.00 to $29.00 and gave the company an "overweight" rating in a report on Friday, November 7th. Morgan Stanley set a $32.00 target price on shares of Omada Health in a research report on Thursday, December 18th. Weiss Ratings restated a "sell (d)" rating on shares of Omada Health in a report on Wednesday, October 8th. Finally, Robert W. Baird began coverage on Omada Health in a research report on Friday, September 5th. They issued a "neutral" rating and a $24.00 price objective for the company. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Omada Health presently has a consensus rating of "Moderate Buy" and an average target price of $27.11.
Check Out Our Latest Stock Analysis on OMDA
Institutional Trading of Omada Health
Institutional investors have recently added to or reduced their stakes in the stock. Fortress Investment Group LLC bought a new stake in shares of Omada Health in the 2nd quarter valued at $2,878,000. Federated Hermes Inc. bought a new stake in Omada Health in the 2nd quarter valued at about $9,150,000. Bellevue Group AG purchased a new stake in shares of Omada Health during the 2nd quarter valued at approximately $4,575,000. Jennison Associates LLC bought a new position in shares of Omada Health in the second quarter worth $4,580,000. Finally, Emerald Advisers LLC bought a new position in Omada Health in the 2nd quarter worth about $5,089,000.
Omada Health Company Profile
(
Get Free Report)
Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company's platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.
In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
